[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589700":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":58,"collaborators":61,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":32,"eligibilityCriteria":72,"healthyVolunteers":69,"sex":73,"minAge":74,"maxAge":32,"enrollmentInfo":75,"targetDuration":32,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":32,"overallStatus":85,"whyStopped":32,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PEGULICIANINE (LUMISIGHT)","EXPERIMENTAL","Twenty (20) participants will receive 1.0 mg\u002Fkg of LUMISIGHT",[13],"Drug: Pegulicianine",{"label":15,"type":16,"description":17,"interventionNames":18},"Normal Saline","PLACEBO_COMPARATOR","Five(5) participants will receive saline injections and be considered controls",[19],"Other: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Pegulicianine","Pegulicianine (LUMISIGHT) Inflammatory activity",[9],[27],"LUMISIGHT",{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Control group for the study",[15],null,[34],{"name":35,"affiliation":5,"role":36},"Guillermo Tearney, MD, PhD","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},"Anita Chung","CONTACT","6177244515","achung7@mgh.harvard.edu",[44],{"facility":5,"status":32,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Boston","Massachusetts","02114","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-71.05977,42.35843,{"lat":54,"lon":53},[57],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},{"type":36,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Guillermo Tearney","Principal Investigator",[62,65],{"name":63,"class":64},"National Institutes of Health (NIH)","NIH",{"name":66,"class":64},"National Heart, Lung, and Blood Institute (NHLBI)","100589700","early-phase-1-study-to-image-inflammatory-activity-of-a-fluorescence-imaging-agent-in-excised-human-artery-plaques-100589700",false,"NCT06957821","Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques","Inclusion Criteria:\n\n* Must have an established diagnosis of severe carotid or peripheral arterial disease (ischemic or aneurysmal) requiring surgery and be sufficiently healthy to undergo surgery\n* Must be age of 18 years or older\n* Must be able to give informed consent\n* Women with childbearing potential must have a negative pregnancy test\n* Estimated glomerular filtration rate ≥ 60 mL\u002Fmin\u002F1.73 m2 (mild renal impairment\n\nExclusion Criteria:\n\n* History of allergic reaction to oral or intravenous contrast agents\n* History of allergic reaction to polyethylene glycol (PEG)\n* History of allergic or anaphylactic reactions\n* Participants who have taken an investigational drug within 14 days of enrollment.\n* Participants with hemodynamic instability\n* Any history of renal failure (estimated Glomerular Filtration Rate (eGFR) \\\u003C60ml\u002Fmin\u002F1.73 m2)\n* Pregnant or lactating females\n* Participants with uncontrolled hypertension defined as persistent systolic blood pressure \\> 180 mm Hg, or diastolic blood pressure \\> 110 mm Hg; those subjects with known HTN should be under these values while under pharmaceutical therapy\n* Severe concurrent illnesses including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, COPD or asthma requiring hospitalization within the past 12 months, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements","ALL","18 Years",{"count":76,"type":77},25,"ESTIMATED","INTERVENTIONAL",[80],"EARLY_PHASE1","Active inflammation plays a key role in causing Coronary Artery Disease (CAD) and Peripheral Arterial Disease (PAD). Since inflammation is so important in how these diseases start, are diagnosed, and treated, being able to see it clearly in each patient could lead to more personalized and effective care - and may help prevent heart attacks. Right now, there's no imaging technology available to clearly see inflammation inside the coronary arteries.\n\nThe investigators hope to learn how an imaging drug; called LUMISIGHT (Pegulicianine) can help detect inflammation in blood vessels compared with saline. If the investigators find out that LUMISIGHT is active in humans, the investigators might be able to use it for detecting plaque risk in the future.",[83,84],"Carotid Artery Diseases","Peripheral Arterial Disease","NOT_YET_RECRUITING","2026-04-15",{"date":88,"type":89},"2026-04-20","ACTUAL",{"date":91,"type":77},"2026-06",{"date":93,"type":77},"2029-12",{"name":5,"class":6},1]